IRIS
VENA, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.036
Totale 5.036
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.036
Totale 5.036
Salva come PNG Salva come JPEG
Città #
Genova 2.105
Genoa 1.562
Rapallo 1.209
Vado Ligure 83
Bordighera 77
Totale 5.036
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 149
Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study 126
Incidence and outcome of invasive candidiasis in intensive care units (icus) in europe: Results of the eucandicu project 115
Treatment of Infections Due to MDR Gram-Negative Bacteria 108
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality 97
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study 93
Coagulative Disorders in Critically Ill COVID-19 Patients with Acute Distress Respiratory Syndrome: A Critical Review 85
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact 81
Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study 81
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 81
Bloodstream infections in critically ill patients with COVID-19 80
A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic 73
Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality 72
Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain 70
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 70
The role of new β-lactamase inhibitors in gram-negative infections 69
Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors 67
Early Detection of Sepsis With Machine Learning Techniques: A Brief Clinical Perspective 65
Diagnosis and Treatment of Candidemia in the Intensive Care Unit 64
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy 64
Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19 62
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 62
Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia 61
Distinct phenotypes require distinct respiratory management strategies in severe COVID-19 59
Emerging treatment options for acute bacterial skin and skin structure infections: Focus on intravenous delafloxacin 59
New antibiotics for ventilator-associated pneumonia 58
Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review 57
Isavuconazole shortens the QTc interval 57
How to manage Pseudomonas aeruginosa infections 55
Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors 55
Management of patients with septic shock due to Candida infection 54
Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/ extensively drug-resistant/pandrug-resistant bacteria 53
Validation of an Automated System for the Extraction of a Wide Dataset for Clinical Studies Aimed at Improving the Early Diagnosis of Candidemia 51
Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study 51
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 51
null 49
Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study 49
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG 48
Risk factors for candidemia after open-heart surgery: results from a multicenter case-control study 48
Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients 46
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study 46
Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study 46
Spread of carbapenem-resistant gram-negatives and candida auris during the covid-19 pandemic in critically ill patients: One step back in antimicrobial stewardship? 44
A comparative analysis of the first and second COVID-19 wave in Italy: evaluation of mortality in the Infectious Disease Unit of Genoa University Hospital 44
Characterization of T lymphocytes in severe COVID-19 patients 44
The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm 43
Rational approach in the management of Pseudomonas aeruginosa infections 42
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study) 42
Antibiotic treatment of acute bacterial skin and skin structure infections 42
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience 41
Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19” 41
Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria 40
High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection 40
Early administration of bamlanivimab in combination with etesevimab increases the benefits of covid-19 treatment: Real-world experience from the liguria region 40
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 39
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales 38
Higher mortality and intensive care unit admissions in COVID-19 patients with liver enzyme elevations 38
The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome 38
Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies 38
Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance 36
Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission 36
Challenges and research priorities to progress the impact of antimicrobial stewardship 34
Molecular epidemiological investigation of a nosocomial cluster of c. Auris: Evidence of recent emergence in italy and ease of transmission during the covid‐19 pandemic 33
COVID-19: Some clinical questions after the first 4 months 33
Early Effects of Passive Leg-Raising Test, Fluid Challenge, and Norepinephrine on Cerebral Autoregulation and Oxygenation in COVID-19 Critically Ill Patients 33
Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians? 33
Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria 32
Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications 31
Antiviral treatment selection for SARS-CoV-2 pneumonia 31
Intermediate monocytes expansion and homing markers expression in COVID-19 patients associate with kidney dysfunction 30
Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients? 30
Aspergillus-PCR in bronchoalveolar lavage - diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients 29
The multifaceted presentation of syphilitic chorioretinitis examined by multimodal imaging: A case series 29
Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective 29
Adequate duration of therapy in severe fungal infections 29
Early versus late intubation in COVID-19 patients failing helmet CPAP: A quantitative computed tomography study 29
Short Course of Antifungal Therapy in Patients With Uncomplicated Candida Bloodstream Infection: Another Case of Less Is More in the Clinical Setting? 28
Reuse of clinical COVID-19 patient data: Pre-processing for future classification 28
Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study 28
Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings 27
Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis 27
Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain 25
Sensitivity of Serum Beta-D-Glucan in Candidemia According to Candida Species Epidemiology in Critically Ill Patients Admitted to the Intensive Care Unit 24
Mould Infections of Traumatic Wounds: A Brief Narrative Review 24
Aspergillus endocarditis in the recent years, report of cases of a multicentric national cohort and literature review 24
Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients 22
Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders 22
null 22
Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant pseudomonas aeruginosa 22
An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia 22
Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape 21
Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2 20
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 20
Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome 20
Treatment of extended-spectrum β-lactamases infections: What is the current role of new β-lactams/β-lactamase inhibitors? 20
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 19
Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care 19
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 19
Antifungal stewardship in daily practice and health economic implications 19
Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression 18
Totale 4.658
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.813
article - articoli 32.813
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020557 0 6 3 13 31 53 115 72 87 99 53 25
2020/2021682 15 45 67 39 40 41 80 67 73 98 70 47
2021/2022963 37 28 37 63 48 40 48 168 184 94 58 158
2022/20231.510 117 135 15 137 172 155 80 96 243 122 184 54
2023/20241.371 57 108 35 173 139 215 126 128 66 50 90 184
2024/2025139 107 32 0 0 0 0 0 0 0 0 0 0
Totale 5.301